← All candidates
Eight insider buys in the last year — $1.29M in all.
92 filings on record.
XRAYDENTSPLY SIRONA Inc.
NasdaqGS · Healthcare · $2.09B
$10.46
-0.38% · Sep 11
Eight insider buys in the last year — $1.29M in all.
Nothing in the last fortnight.
Price · 1Y · daily● 8 buys● 1 sell◆ 7 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$2.09B
Float
188.0M
94% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
6.9
Price / sales
0.6
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Lucier Gregory T
Bought $392.5K on Mar 2 — 27,555 sh @ $14.25, held indirect, 100% of their stake.
2 of 3 positions beat the S&P
Director
Barber Michael J
Bought $150.0K on Jun 11 — 15,175 sh @ $9.89, held direct, 27% of their stake.
No completed positions to measure
Director
Mazelsky Jonathan Jay
Bought $101.4K on Jun 12 — 10,000 sh @ $10.14, held direct, 16% of their stake.
No completed positions to measure
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
84 more transactions on Pro →Context
Wall St
$13.40 avg target
+28.1% vs today · 15 analysts · consensus Hold
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q1 '26$0.27 act−$0.00
Q4 '25$0.27 act−$0.02
Q3 '25$0.37 act−$0.08
Q2 '25$0.52 act+$0.02
Coverage
How DENTSPLY SIRONA’s New Veteran CFO Could Shape Capital Allocation and Strategy for XRAY InvestorsSimply Wall St. · 06-15Dentsply (XRAY) Down 13.5% Since Last Earnings Report: Can It Rebound?Zacks · 06-04How Dentsply Sirona’s Expanded Nashville Dental Partnership Could Impact DENTSPLY SIRONA (XRAY) InvestorsSimply Wall St. · 05-31Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To KnowStockStory · 05-17
The file stays open
92 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice